Role of the polypill for secondary prevention in ischaemic heart disease

José M Castellano; Valentín Fuster; Catriona Jennings; Eva Prescott; Héctor Bueno

doi:10.1177/2047487317707324

Role of the polypill for secondary prevention in ischaemic heart disease

José M Castellano, Valentín Fuster, Catriona Jennings, Eva Prescott, Héctor Bueno

Department of Clinical Medicine

7 Citations (Scopus)

Abstract

In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition. At the same time, the increase in cardiovascular risk factors, together with a decline in mortality in high-income countries in the past two decades, has led to a significant upsurge in the prevalence of secondary prevention of ischaemic heart disease. With this, the effect that non-adherence to cardioprotective drugs is having has become progressively clear, both in terms of clinical outcomes and as a driver of increased healthcare expenditure. The cardiovascular polypill, which was originally proposed as a strategy to improve accessibility to cardioprotective drugs worldwide, has proven to be a mainstay therapeutic approach for improving medication adherence in cardiovascular disease. In the current paper, we aim to review the need for a polypill strategy in the present scenario of cardiovascular disease, the available data that support such a strategy and the various clinical trials that are in progress that will help further shape future indications for the cardiovascular polypill.

Original language	English
Journal	European Journal of Preventive Cardiology
Volume	24
Issue number	3_suppl
Pages (from-to)	44-51
Number of pages	8
ISSN	2047-4873
DOIs	https://doi.org/10.1177/2047487317707324
Publication status	Published - Jun 2017

Keywords

Administration, Oral
Cardiovascular Agents/administration & dosage
Cost-Benefit Analysis
Disease Progression
Drug Combinations
Drug Costs
Humans
Medication Adherence
Myocardial Ischemia/drug therapy
Recurrence
Risk Factors
Secondary Prevention/economics
Tablets
Treatment Outcome

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1177/2047487317707324

2047487317707324Final published version, 434 KB

Cite this

@article{0f0466e44dd5438c86821d0a0b66f619,

title = "Role of the polypill for secondary prevention in ischaemic heart disease",

abstract = "In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition. At the same time, the increase in cardiovascular risk factors, together with a decline in mortality in high-income countries in the past two decades, has led to a significant upsurge in the prevalence of secondary prevention of ischaemic heart disease. With this, the effect that non-adherence to cardioprotective drugs is having has become progressively clear, both in terms of clinical outcomes and as a driver of increased healthcare expenditure. The cardiovascular polypill, which was originally proposed as a strategy to improve accessibility to cardioprotective drugs worldwide, has proven to be a mainstay therapeutic approach for improving medication adherence in cardiovascular disease. In the current paper, we aim to review the need for a polypill strategy in the present scenario of cardiovascular disease, the available data that support such a strategy and the various clinical trials that are in progress that will help further shape future indications for the cardiovascular polypill.",

keywords = "Administration, Oral, Cardiovascular Agents/administration & dosage, Cost-Benefit Analysis, Disease Progression, Drug Combinations, Drug Costs, Humans, Medication Adherence, Myocardial Ischemia/drug therapy, Recurrence, Risk Factors, Secondary Prevention/economics, Tablets, Treatment Outcome",

author = "Castellano, {Jos{\'e} M} and Valent{\'i}n Fuster and Catriona Jennings and Eva Prescott and H{\'e}ctor Bueno",

year = "2017",

month = jun,

doi = "10.1177/2047487317707324",

language = "English",

volume = "24",

pages = "44--51",

journal = "European Journal of Preventive Cardiology",

issn = "2047-4873",

publisher = "SAGE Publications",

number = "3_suppl",

}

TY - JOUR

T1 - Role of the polypill for secondary prevention in ischaemic heart disease

AU - Castellano, José M

AU - Fuster, Valentín

AU - Jennings, Catriona

AU - Prescott, Eva

AU - Bueno, Héctor

PY - 2017/6

Y1 - 2017/6

N2 - In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition. At the same time, the increase in cardiovascular risk factors, together with a decline in mortality in high-income countries in the past two decades, has led to a significant upsurge in the prevalence of secondary prevention of ischaemic heart disease. With this, the effect that non-adherence to cardioprotective drugs is having has become progressively clear, both in terms of clinical outcomes and as a driver of increased healthcare expenditure. The cardiovascular polypill, which was originally proposed as a strategy to improve accessibility to cardioprotective drugs worldwide, has proven to be a mainstay therapeutic approach for improving medication adherence in cardiovascular disease. In the current paper, we aim to review the need for a polypill strategy in the present scenario of cardiovascular disease, the available data that support such a strategy and the various clinical trials that are in progress that will help further shape future indications for the cardiovascular polypill.

AB - In 2011, for the first time in the history of humankind, non-communicable diseases became the leading cause of death worldwide. This change in trend is obviously multifactorial and very complex, as it is the paradoxical result of social, economic and health system growth worldwide. Vaccination and infectious diseases control, changing dietary habits worldwide, sedentary behaviour, globalisation, industrialisation (resulting in a shift from manual to sedentary labour), tobacco and sugary beverage surges in low- and middle-income countries and rapid urbanisation have all played a role in this epidemic transition. At the same time, the increase in cardiovascular risk factors, together with a decline in mortality in high-income countries in the past two decades, has led to a significant upsurge in the prevalence of secondary prevention of ischaemic heart disease. With this, the effect that non-adherence to cardioprotective drugs is having has become progressively clear, both in terms of clinical outcomes and as a driver of increased healthcare expenditure. The cardiovascular polypill, which was originally proposed as a strategy to improve accessibility to cardioprotective drugs worldwide, has proven to be a mainstay therapeutic approach for improving medication adherence in cardiovascular disease. In the current paper, we aim to review the need for a polypill strategy in the present scenario of cardiovascular disease, the available data that support such a strategy and the various clinical trials that are in progress that will help further shape future indications for the cardiovascular polypill.

KW - Administration, Oral

KW - Cardiovascular Agents/administration & dosage

KW - Cost-Benefit Analysis

KW - Disease Progression

KW - Drug Combinations

KW - Drug Costs

KW - Humans

KW - Medication Adherence

KW - Myocardial Ischemia/drug therapy

KW - Recurrence

KW - Risk Factors

KW - Secondary Prevention/economics

KW - Tablets

KW - Treatment Outcome

U2 - 10.1177/2047487317707324

DO - 10.1177/2047487317707324

M3 - Journal article

C2 - 28618914

SN - 2047-4873

VL - 24

SP - 44

EP - 51

JO - European Journal of Preventive Cardiology

JF - European Journal of Preventive Cardiology

IS - 3_suppl

ER -

Role of the polypill for secondary prevention in ischaemic heart disease

Abstract

Keywords

UN SDGs

Access to Document

Fingerprint

Cite this